People: Vanda Pharmaceuticals Inc (VNDA.W)

VNDA.W on CBOE When Trading NASDAQ Global Select Market

7.12USD
23 May 2013
Price Change (% chg)

$0.15 (+2.15%)
Prev Close
$6.97
Open
$6.82
Day's High
$7.20
Day's Low
$6.75
Volume
2,000
Avg. Vol
701
52-wk High
$7.44
52-wk Low
$3.00

Search Stocks

Summary

Name Age Since Current Position

Howard Pien

 54 2010 Independent Chairman of the Board

Mihael Polymeropoulos

 52 2010 President, Chief Executive Officer, Director

James Kelly

 46 2010 Chief Financial Officer, Senior Vice President, Treasurer, Secretary

Paolo Baroldi

 2013 Senior Vice President, Chief Medical Officer

Robert Repella

 53 2011 Senior Vice President, Chief Commercial Officer

Michael Cola

 53 2012 Independent Director

Richard Dugan

 70 2005 Independent Director

Steven Galson

 55 2010 Independent Director

Vincent Milano

 49 2010 Independent Director

H. Thomas Watkins

 59 2006 Independent Director

Cristina Murphy

 IR Contact
» Insider Trading

Biographies

Name Description

Howard Pien

 Mr. Howard H. Pien is Independent Chairman of the Board of Vanda Pharmaceuticals Inc. Mr. Pien served as President and Chief Executive Officer and a director of Medarex, Inc from June 2007 until it was acquired by Bristol-Myers Squibb Co. in September, 2009. Prior to his tenure at Medarex, Mr. Pien served as President and Chief Executive Officer of Chiron Corporation until April 2006 when it was acquired by Novartis. He joined Chiron from GlaxoSmithKline (formerly SmithKline Beecham), where he served as President, Pharmaceuticals for SmithKline Beecham and later as President of GlaxoSmithKline’s International Pharmaceuticals business. Mr. Pien has also held positions in sales, market research, licensing and product management at Abbott Laboratories and Merck & Co. Mr. Pien currently serves as a director of ViroPharma Incorporated and Immunogen, Inc., both public companies engaged in drug development as well as Ikaria, a private company engaged in life sciences. Mr. Pien previously served on the boards of Oakland Children’s Hospital, Chiron, and Medarex. Mr. Pien earned a B.S. from the Massachusetts Institute of Technology and an M.B.A. from Carnegie-Mellon University.

Mihael Polymeropoulos

 Dr. Mihael H. Polymeropoulos, M.D., is President, Chief Executive Officer, Director of Vanda Pharmaceuticals Inc. Prior to joining Vanda, Dr. Polymeropoulos was Vice President and Head of the Pharmacogenetics Department at Novartis AG from 1998 to 2003. Prior to his tenure at Novartis, he served as Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, National Human Genome Research Institute, from 1992 to 1998. Dr. Polymeropoulos is the co-founder of the Integrated Molecular Analysis of Genome Expression (IMAGE) Consortium. Dr. Polymeropoulos holds a degree in Medicine from the University of Patras.

James Kelly

 Mr. James Patrick Kelly is Chief Financial Officer, Senior Vice President, Treasurer, Secretary of Vanda Pharmaceuticals Inc., since December 13, 2010. Mr. Kelly brings more than 20 years of experience in financial and operating roles within the healthcare and pharmaceutical industry. Prior to joining Vanda, Mr. Kelly was Vice President and Controller at MedImmune, a biotechnology subsidiary of the AstraZeneca Group. Mr. Kelly joined MedImmune in 2006 as Director of Sales and Marketing Finance. From 2000 through 2005, Mr. Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the Director of Planning and Operations. From 1997-2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc. which was responsible for mergers and acquisitions and treasury management. Mr. Kelly began his life sciences career in 1991 with Janssen Pharmaceutical, a division of Johnson & Johnson. Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (ABFO). He received his Master of Business Administration degree from Cornell University and his Bachelor of Sciences degree in Business Administration from the University of Vermont.

Paolo Baroldi

 Dr. Paolo Baroldi, M.D., Ph.D., is Senior Vice President and Chief Medical Officer at Vanda Pharmaceuticals Inc. Prior to joining Vanda, Dr. Baroldi served as Vice President-Corporate Drug Development at Chiesi Farmaceutici SpA, in Parma, Italy, from 2003 to 2006. Prior to his tenure at Chiesi, Dr. Baroldi was the Global Head of Clinical Pharmacology at Novartis AG from 1998 to 2002. Dr. Baroldi holds degrees in Medicine and Surgery and a Ph.D. in Clinical Pharmacology from the University of Milan and an Executive M.B.A. from Harvard University.

Robert Repella

 Mr. Robert Repella serves as Senior Vice President, Chief Commercial Officer of Vanda Pharmaceuticals Inc. Prior to accepting employment with the Company, Mr. Repella served as Senior Vice President of Pharmaceutical Operations for the Americas Region at Cephalon, Inc. since October of 2009. Prior to Cephalon, and beginning in 2000, Mr. Repella was at Wyeth Pharmaceuticals in a number of roles, most recently as Executive Vice President and General Manager of the Biopharma business unit. In this position, Mr. Repella was responsible for the global portfolio of products that included Wyeth’s biologic, Enbrel®. During his 16 years at Wyeth, Mr. Repella served in various roles in both Marketing and Sales including Executive Vice President Pharmaceutical Sales, Marketing and Operations; Senior Vice President of Pharmaceutical Sales; Vice President of Global Business Manager, Enbrel; Vice President of U. S. Marketing, Musculoskeletal Products; Vice President of U. S. Healthcare Systems Sales, and Assistant Vice President National Accounts. Earlier in his career, Mr. Repella held positions with Johnson & Johnson’s McNeil Pharmaceutical Division, Merck & Co., Inc. and Eli Lilly & Co. Mr. Repella serves as a director at The Pennsylvania Biotechnology Association. Mr. Repella is a member of several boards including BIO, where he also serves on their Executive Committee, and Pennsylvania BIO. Mr. Repella holds a Bachelor’s degree in Pharmacy from Rutgers University and a Masters in Business Administration from Temple University.

Michael Cola

 Mr. Michael F. Cola has been appointed as Independent Director of Vanda Pharmaceuticals Inc., effective June 14, 2012. Mr. Cola served as President of Shire plc's Specialty Pharmaceuticals business from 2007 until April 2012. Mr. Cola joined Shire in July 2005 as Executive Vice President for Global Therapeutic Business Units and Portfolio Management prior to being named President of the Specialty Pharmaceuticals business. Prior to joining Shire, Mr. Cola spent more than five years at Safeguard Scientifics, where he served as President of the Life Sciences Group. As part of his role with Safeguard Scientifics, Cola served as Chairman and CEO of Clarient, a cancer diagnostics company, and Chairman of Laureate Pharma, a full service contract manufacturing organization serving research based biologics companies. Prior to joining Safeguard Scientifics, Mr. Cola held progressively senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and later with AstraZeneca. Mr. Cola currently serves on the Board of Directors of NuPathe Pharmaceuticals, is a member of the Board of Trustees of Ursinus College, and a member of the Board of Directors of Pennsylvania Bio, the statewide association representing the biosciences community. Mr. Cola received his Bachelor of Arts degree in biology and physics from Ursinus College and his Master of Science degree in biomedical science from Drexel University.

Richard Dugan

 Mr. Richard W. Dugan serves as Independent Director of Vanda Pharmaceuticals Inc., since December of 2005. He served as a Partner with Ernst & Young, LLP from 1976 to September 2002, where he served in a variety of managing and senior partner positions, including Mid-Atlantic Area Senior Partner from 2001 to 2002, Mid-Atlantic Area Managing Partner from 1989 to 2001 and Pittsburgh Office Managing Partner from 1979 to 1989. Mr. Dugan retired from Ernst & Young, LLP in September 2002. Mr. Dugan previously served as a director of two publicly traded pharmaceutical companies, Middlebrook Pharmaceuticals, Inc. and Critical Therapeutics, Inc., and a privately-owned pharmaceutical company, Xanthus Pharmaceuticals. Mr. Dugan holds a B.S.B.A. from Pennsylvania State University.

Steven Galson

 Dr. Steven K. Galson, M.D., M.P.H., serves as Independent Director of Vanda Pharmaceuticals Inc., since July 1, 2010. Dr. Galson is the Vice President for Global Regulatory Affairs at Amgen, a biopharmaceuticals company. Prior to Amgen, Dr. Galson was Senior Vice President for Civilian Health Operations at Science Applications International Corporation (“SAIC”), a scientific, engineering and technology applications company. Prior to joining SAIC, Dr. Galson was the Acting U.S. Surgeon General. Prior to that, Dr. Galson was the Director of the Food and Drug Administration’s Center for Drug Evaluation and Research. Dr. Galson also held executive positions in the U.S. Environmental Protection Agency, U.S. Department of Energy and the Centers for Disease Control and Prevention’s National Institute for Occupational Safety and Health. Dr. Galson received his Bachelor of Science degree in biochemistry from the State University of New York at Stony Brook, his Doctor of Medicine degree from the Mt. Sinai School of Medicine and his Master of Public Health degree from the Harvard School of Public Health.

Vincent Milano

 Mr. Vincent J. Milano serves as Independent Director of Vanda Pharmaceuticals Inc., since April 21, 2010. Mr. Milano has served as President and Chief Executive Officer of ViroPharma Incorporated since March 2008. Mr. Milano served as Chief Operating Officer from January 2006 to March 2008, and as Vice President, Chief Financial Officer of ViroPharma from November 1997 to March 2008. Mr. Milano also previously served as Vice President, Finance & Administration, Treasurer, and as Executive Director, Finance & Administration of ViroPharma. Prior to joining ViroPharma, Mr. Milano was with KPMG LLP, independent certified public accountants, where he was a Senior Manager from 1991 to 1996. Mr. Milano received his Bachelor of Science degree in Accounting from Rider College.

H. Thomas Watkins

 Mr. H. Thomas Watkins serves as Independent Director of Vanda Pharmaceuticals Inc., since September 2006. Mr. Watkins has served as the President and Chief Executive Officer of Human Genome Sciences, Inc. and as a member of its Board of Directors since 2005. Prior to his tenure at Human Genome Sciences Inc., Mr. Watkins served as President of TAP Pharmaceutical Products, Inc. Mr. Watkins previously held a series of executive positions over the course of nearly twenty years with Abbott Laboratories. Mr. Watkins also serves on the Board of Directors of the Biotechnology Industry Organization (BIO), and has served as Chair of the BIO Board of Directors since June, 2011. He holds a B.B.A. from the College of William and Mary and an M.B.A from the University of Chicago Graduate School of Business.

Cristina Murphy

Basic Compensation

Name Fiscal Year Total

Howard Pien

 --

Mihael Polymeropoulos

 1,484,520

James Kelly

 692,478

Paolo Baroldi

 6,152

Robert Repella

 1,269,180

Michael Cola

 --

Richard Dugan

 --

Steven Galson

 --

Vincent Milano

 --

H. Thomas Watkins

 --

Cristina Murphy

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Howard Pien

 0 0

Mihael Polymeropoulos

 961,475 1,724,730

James Kelly

 0 0

Paolo Baroldi

 80,605 304,230

Robert Repella

 0 0

Michael Cola

 0 0

Richard Dugan

 0 0

Steven Galson

 0 0

Vincent Milano

 0 0

H. Thomas Watkins

 0 0

Cristina Murphy

 0 0

Insider Trading

Name Shares Traded Price

POLYMEROPOULOS MIHAEL HRISTOS

 12,500 $0.00

REPELLA ROBERT

 15,000 $0.00

POLYMEROPOULOS MIHAEL HRISTOS

 18,750 $0.00

POLYMEROPOULOS MIHAEL HRISTOS

 16,836 $3.95

KELLY JAMES PATRICK

 6,978 $3.95

KELLY JAMES PATRICK

 12,500 $0.00

POLYMEROPOULOS MIHAEL HRISTOS

 12,500 $0.00

KELLY JAMES PATRICK

 4,687 $0.00

FEENEY JOHN JOSEPH

 4,687 $0.00

POLYMEROPOULOS MIHAEL HRISTOS

 12,500 $0.00

FEENEY JOHN JOSEPH

 4,760 $4.65

FEENEY JOHN JOSEPH

 7,500 $0.00

KELLY JAMES PATRICK

 4,920 $4.67

POLYMEROPOULOS MIHAEL HRISTOS

 11,350 $4.69

POLYMEROPOULOS MIHAEL HRISTOS

 18,750 $0.00

KELLY JAMES PATRICK

 12,500 $0.00

KELLY JAMES PATRICK

 5,000 $5.99

POLYMEROPOULOS MIHAEL HRISTOS

 7,920 $5.35

POLYMEROPOULOS MIHAEL HRISTOS

 2,080 $5.34
» Full list on Insider Trading
Search Stocks